This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
Subscribe To Our Newsletter & Stay Updated
